Search Results | Blood | American Society of Hematology

1-20 of 159

Sort by

Sort Order Select

Journal Articles

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Blood (2023) 141 (21): 2657–2661.

DOI: https://doi.org/10.1182/blood.2022019160

Published: 2023

Includes: Supplemental data

Journal Articles

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Blood (2023) 141 (13): 1610–1625.

DOI: https://doi.org/10.1182/blood.2021011094

Published: 2023

Includes: Supplemental data

Journal Articles

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Jesse M. Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Thomas Fischer, Bjørn Tore Gjertsen, Patrycja Gradowska, Laimonas Griskevicius, Jeroen J.W.M. Janssen, Gunnar Juliusson, Johan A. Maertens, Markus G Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter JM Valk, Bob Lowenberg, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2022) 140 (Supplement 1): 2027–2029.

DOI: https://doi.org/10.1182/blood-2022-157009

Published: 2022

Journal Articles

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Blood (2022) 140 (Supplement 1): 2020–2022.

DOI: https://doi.org/10.1182/blood-2022-159391

Published: 2022

Journal Articles

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Joseph Saad, Samuli Eldfors, Vilma Ikonen, Bjørn Tore Gjertsen, Mika Kontro, Kimmo Porkka, Caroline A. Heckman

Blood (2022) 140 (Supplement 1): 1033–1035.

DOI: https://doi.org/10.1182/blood-2022-163242

Published: 2022

Journal Articles

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Blood (2022) 140 (Supplement 1): 1030–1032.

DOI: https://doi.org/10.1182/blood-2022-159069

Published: 2022

Journal Articles

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 101–103.

DOI: https://doi.org/10.1182/blood-2022-158694

Published: 2022

Journal Articles

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Blood (2022) 140 (Supplement 1): 9125–9127.

DOI: https://doi.org/10.1182/blood-2022-157753

Published: 2022

Journal Articles

Integrated High-Throughput Drug Profiling and CRISPR Screening Identify Novel Pathway Vulnerabilities of Leukemic Stem Cells in Chronic Myeloid Leukemia

Shady Adnan Awad, Olli Dufva, Jay Klievink, Ella Karjalainen, Aleksandr Ianevski, Paavo Pietarinen, Daehong Kim, Swapnil Potdar, Maija Wolf, Kourosh Lotfi, Tero Aittokallio, Krister Wennerberg, Kimmo Porkka, Satu Mustjoki

Blood (2022) 140 (Supplement 1): 799–800.

DOI: https://doi.org/10.1182/blood-2022-165247

Published: 2022

Journal Articles

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R. Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther T. Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes

Blood (2022) 140 (15): 1674–1685.

DOI: https://doi.org/10.1182/blood.2022016293

Published: 2022

Includes: Supplemental data

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

DOI: https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

Gail J. Roboz, Farhad Ravandi, Andrew H. Wei, Hervé Dombret, Felicitas Thol, Maria Teresa Voso, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Jianhua Zhong, C. L. Beach, Alberto Risueño, Daniel L. Menezes, Gert Ossenkoppele, Hartmut Döhner

Blood (2022) 139 (14): 2145–2155.

DOI: https://doi.org/10.1182/blood.2021013404

Published: 2022

Includes: Supplemental data

Journal Articles

Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial

Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, Amanda Ranta, Tanja Ruokoranta, Annasofia Holopainen, Sirpa Koskela, Milla E.L. Kuusisto, Kimmo Porkka, Riikka Räty, Imre Västrik, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Mika Kontro

Blood (2021) 138 (Supplement 1): 228.

DOI: https://doi.org/10.1182/blood-2021-147691

Published: 2021

Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Blood (2021) 138 (Supplement 1): 244.

DOI: https://doi.org/10.1182/blood-2021-146039

Published: 2021

Journal Articles

ATR/CHK1/WEE1 Dependency in SRSF2 -Mutated MDS/AML

Samuli Eldfors, Sumit Rai, Vineet Sharma, Angelique N Gilbert, Kimmo Porkka, Timothy A. Graubert

Blood (2021) 138 (Supplement 1): 3661.

DOI: https://doi.org/10.1182/blood-2021-147960

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

Andrew M. Brunner, Elie Traer, Norbert Vey, Sebastian Scholl, Natalia Tovar, Kimmo Porkka, Rupa Narayan, Guillermo Garcia-Manero, Steve Knapper, Martin Wermke, Jeroen J. Janssen, Jordi Esteve, Sun Loo, Mika Kontro, Zachariah Defilipp, Andrew H. Wei, Uma Borate

Blood (2021) 138 (Supplement 1): 3677.

DOI: https://doi.org/10.1182/blood-2021-151455

Published: 2021

Journal Articles

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes

Blood (2021) 138 (Supplement 1): 804.

DOI: https://doi.org/10.1182/blood-2021-147465

Published: 2021

Journal Articles

Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS

Blood (2021) 138 (Supplement 1): 801.

DOI: https://doi.org/10.1182/blood-2021-147150

Published: 2021

Journal Articles

Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial

Andrew H. Wei, Hartmut Döhner, Hamid Sayar, Farhad Ravandi, Pau Montesinos, Hervé Dombret, Dominik Selleslag, Kimmo Porkka, Jun Ho Jang, Barry Skikne, C.L. Beach, Yu (Olivia) Tian, Gail J. Roboz

Blood (2021) 138 (Supplement 1): 871.

DOI: https://doi.org/10.1182/blood-2021-147501

Published: 2021

Journal Articles

Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)

Andrew H. Wei, Massimo Breccia, Melissa Ooi, Maria Teresa Cedena Romero, Fabio Ciceri, Harry P. Erba, Anil Gaur, Romain Sechaud, Ensar Halilovic, Brigitte Kuenzle, Claire Fabre, Kimmo Porkka

Blood (2021) 138 (Supplement 1): 1283.

DOI: https://doi.org/10.1182/blood-2021-144650

Published: 2021

NARROW

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Integrated High-Throughput Drug Profiling and CRISPR Screening Identify Novel Pathway Vulnerabilities of Leukemic Stem Cells in Chronic Myeloid Leukemia

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

ATR/CHK1/WEE1 Dependency in SRSF2 -Mutated MDS/AML

Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS

Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial

Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only